Genevieve Contant
Overview
Explore the profile of Genevieve Contant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Helms J, Curtiaud A, Severac F, Tschirhart M, Merdji H, Bourdin M, et al.
Anesthesiology
. 2024 Mar;
141(1):75-86.
PMID: 38502917
Background: Extracorporeal membrane oxygenation (ECMO) is associated with a high risk of bleeding complications. The specific impact of ECMO on fibrinolysis remains unexplored. The objective of the current pilot observational...
2.
Ullah M, Mirshahi S, Valinattaj Omran A, Aldybiat I, Crepaux S, Soria J, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473289
Background: Blood viscoelasticity and plasma protein levels can play an important role in the diagnosis and prognosis of cancer. However, the role of histones and DNA in modulating blood clot...
3.
Heng E, Neuwirth M, Mas F, Contant G, Mazighi M, Feriel J, et al.
Cytometry A
. 2023 Nov;
105(3):171-180.
PMID: 37971361
Background: Innovative tools to reliably identify patients with acute stroke are needed. Peripheral monocyte subsets, that is, classical-Mon1, intermediate-Mon2, and non-classical-Mon3, with their activation marker expression analyzed using flow-cytometry (FCM)...
4.
Bourdin M, Perrotin D, Mathieu O, Herve T, Depasse F, Lu G, et al.
Int J Lab Hematol
. 2021 Jun;
43(4):795-801.
PMID: 34092030
Introduction: Andexanet alfa (AnXa) was developed for anticoagulant effect reversal of direct factor Xa inhibitors (DXaI) (apixaban, rivaroxaban, edoxaban) in emergency situations. Regular anti-Xa assays are not suitable to evaluate...
5.
Sevenet P, Cucini V, Herve T, Depasse F, Carlo A, Contant G, et al.
Int J Lab Hematol
. 2020 Jun;
42(5):636-642.
PMID: 32567799
Introduction: Directs oral anticoagulants (DOACs) can interfere with coagulation assays, especially in thrombophilia workup. To avoid these interferences, a new device, DOAC Filter, allows the removal of DOACs from citrated...
6.
Shah S, Fourgeaud C, Derieux S, Mirshahi S, Contant G, Pimpie C, et al.
Oncotarget
. 2018 Oct;
9(73):33778-33787.
PMID: 30333909
Heparanase (HPSE), a heparan sulfate-specific endo-β-D-glucuronidase, plays an important role in tumor cell metastasis through the degradation of extracellular matrix heparan sulfate proteoglycans. Suramin, a polysulfonated naphthylurea, is an inhibitor...
7.
Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C, et al.
Thromb J
. 2013 Jul;
11(1):11.
PMID: 23822763
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases...
8.
Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C, et al.
Clin Appl Thromb Hemost
. 2012 Mar;
18(2):150-8.
PMID: 22387577
This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated...
9.
Samama M, Contant G, Spiro T, Perzborn E, Guinet C, Gourmelin Y, et al.
Thromb Haemost
. 2011 Dec;
107(2):379-87.
PMID: 22187012
Rivaroxaban is an oral, direct factor Xa inhibitor. Routine coagulation monitoring is not required, but a quantitative determination of rivaroxaban concentrations might be useful in some clinical circumstances. This multicentre...